Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer
After adjusting for treatment selection bias, RCT OS and RCT rPFS estimates serve as useful, or even conservative, predictors of RW OS gains.
Authors
- Bhakti Arondekar (ORCID: https://orcid.org/0000-0002-4553-0094)
- Alexander Niyazov (ORCID: https://orcid.org/0000-0003-1292-9661)
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- Neal Masia (ORCID: https://orcid.org/0009-0007-2438-6058)
- Darius Lakdawalla (ORCID: https://orcid.org/0000-0001-5934-8042)
- Sarah Axeen (ORCID: https://orcid.org/0000-0002-1538-0013)
- Alice Chen (ORCID: https://orcid.org/0000-0002-7908-2664)
Institutions
- University of Southern California (US)
- Cedars-Sinai Medical Center (US)
- Pfizer (United States) (US)
- Columbia University (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1093/jncics/pkaf018
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer